HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (3- (4- butylpiperidin- 1- yl)propyl)- 7- fluoro- 4H- benzo(1,4)oxazin- 3- one

structure in first source

Also Known As:

AC 260584; AC-260584; AC260584

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - Benzoxazines: 58
      - 4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzoxazines: 58
      - 4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one: 3

Experts

1.	Bonhaus, Douglas W: 2 articles (02/2010 - 10/2007)
2.	Davis, Robert E: 2 articles (02/2010 - 06/2008)
3.	Bajpai, Abhishek: 1 article (02/2010)
4.	Bradley, Stefania Risso: 1 article (02/2010)
5.	Burstein, Ethan S: 1 article (02/2010)
6.	Friberg, Mikael: 1 article (02/2010)
7.	Lameh, Jelveh: 1 article (02/2010)
8.	McFarland, Krista: 1 article (02/2010)
9.	Nguyen, Derek: 1 article (02/2010)
10.	Ohrmund, Linda: 1 article (02/2010)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 10/31/2007 - "Therefore, AC260584, as well as other muscarinic M1 receptor agonists, may be a valuable target for the development of drugs which can improve the cognitive deficits in schizophrenia and perhaps other neuropsychiatric disorders, as well." 02/01/2010 - "Therefore, AC-260584 may serve as a lead compound in the development of M(1) selective drugs for the treatment of cognitive impairment associated with schizophrenia and Alzheimer's disease."
2.	Cognitive Dysfunction 02/01/2010 - "Therefore, AC-260584 may serve as a lead compound in the development of M(1) selective drugs for the treatment of cognitive impairment associated with schizophrenia and Alzheimer's disease."
3.	Catalepsy 06/01/2008 - "In contrast to haloperidol, AC-260584 did not produce catalepsy. " 06/01/2008 - "AC-260584 was evaluated in animal models: antipsychotic-like effects were tested by the ability to reduce amphetamine- and MK-801-induced hyperactivity and apomorphine-induced climbing; catalepsy was assessed by measuring step-down latency; spatial memory was tested by using the Morris water maze. "
4.	Alzheimer Disease (Alzheimer's Disease) 02/01/2010 - "Therefore, AC-260584 may serve as a lead compound in the development of M(1) selective drugs for the treatment of cognitive impairment associated with schizophrenia and Alzheimer's disease."

Related Drugs and Biologics

1.	Muscarinic M1 Receptor
2.	Antipsychotic Agents (Antipsychotics)
3.	Haloperidol (Haldol)
4.	Apomorphine
5.	Amphetamine (Amfetamine)